BOYDS - Key Persons

Job Titles:

• Honorary Professor
• Professor

Professor Alan Boyd is the President and CEO of Boyds. He founded the company in 2005 to support the translation of ideas into medicinal products and treatments for patient benefit. He has since grown the company globally with offices in the UK, Ireland and the US. In 2009, Professor Boyd was appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School. He is also a Fellow at the Faculty of Pharmaceutical Medicine, Royal College of Physicians, where he has undertaken many officer roles over several years. In 2015, Alan was elected President of the Faculty of Pharmaceutical Medicine, a position he held for four years. Through his work at the Faculty, he has made significant contributions to the establishment of the specialty training programme in pharmaceutical medicine, which has now resulted in around 400 post-graduate trainees receiving a CCT in the specialty. In 2021, he was awarded a Fellowship of the Academy of Medical Sciences in recognition of his significant involvement in supporting the development of medicines across several therapeutic areas, most notably in the field of cell and gene advanced therapeutics. Alan career originally began with Glaxo Group Research Ltd. Then from 1988, he led ICI's cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma in Canada. In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular, he led the development of their gene-based medicines portfolio. In April 2005, he left to set up Boyds. The focus of which is to aid and support early-stage life-science-based companies and universities particularly in the translation and development of their research ideas into therapeutics. His contribution to medicines development has resulted in so far, over fifteen products being licensed as prescription medicines and this includes nine cell and gene therapies.

Job Titles:

• Member of the Editorial Panel
• Regulatory Consultant at GFA
• Vice President of Regulatory Affairs and Leads
• VICE PRESIDENT, REGULATORY AFFAIRS

Dr Julie Warner is Vice President of Regulatory Affairs and leads the award-winning regulatory team, supporting clients across the globe. An experienced regulatory professional, Julie completed her PhD in 2002 at the University of Newcastle. After spending some time in research at the University of Cambridge and the biotech company AdProTech, Julie then joined Gregory Fryer Associates (GFA) in 2003. As a Regulatory Consultant at GFA, Julie co-ordinated and managed projects on behalf of clients, ranging from EU and US orphan drug designation applications, to Protocol Assistance/ Scientific Advice, multinational clinical trial applications and marketing authorisation applications. During this time, Julie provided strategic and operational regulatory support for the programmes and managed interactions and negotiations with regulatory authorities in both the EU and US. In 2008, Julie joined Genzyme Europe Research in Cambridge where she was responsible for their cardiovascular portfolio, taking a novel therapy from mid-stage clinical development through to marketing authorisation application. From there, she moved to Clovis Oncology UK and was responsible for preparing and maintaining regulatory submissions for the product portfolio. In 2013, Julie was appointed Senior Regulatory Programme Manager at Roche Products, working on an oncology development project. Julie joined Boyds in August 2014 to strengthen the existing regulatory affairs team and in 2016, she became Director of Regulatory Affairs. Bringing a wealth of experience in EU and US regulatory affairs, Julie has a special interest in orphan drugs. Julie has been a member of the Editorial Panel for the professional journal of The Organisation for Professionals in Regulatory Affairs (TOPRA), the Regulatory Rapporteur, for over 10 years, and in 2015 became a Fellow of TOPRA.

Job Titles:

• Chief Medical Officer and Vice President, Clinical and Medical Affairs
• VICE PRESIDENT, CLINICAL and MEDICAL AFFAIRS and CHIEF MEDICAL OFFICER

Dr Karen Mullen FFPM joined Boyds in 2022 as Chief Medical Officer (CMO) and Vice President of Clinical and Medical Affairs. A highly skilled pharmaceutical physician with more than 20 years' experience in medical affairs and drug research and development, Karen has worked in Europe, the USA and Australia across a wide range of pharmaceutical therapy areas, including vaccines, cell and gene therapies and oncology. Karen is the Chief Medical Officer and leads our Clinical and Medical Affairs department and its team of pharmaceutical physicians, providing medical monitoring support, and safety, pharmacovigilance, scientific and medical advice across a wide range of client projects including advanced therapies, orphan drugs and oncology. She joined Boyds from GlaxoSmithKline, where she was Country Medical Director for the UK and Ireland and responsible for leading and managing a large medical department across clinical research, pharma, and vaccines. Her previous roles at GSK include Head of Medical Affairs, Director of Vaccines, and Director of Metabolic Medicine. Karen is a Fellow of Faculty of Pharmaceutical Medicine (FFPM) and was a member of the Prescription Medicines Code of Practice Authority (PMCPA) Appeal Board for three years. Previously, she also chaired the Association of the British Pharmaceutical Industry (ABPI) Code of Practice Working Group on behalf of the Faculty of Pharmaceutical Medicine (FPM) as well as being involved in various other ABPI working groups.

Job Titles:

• VICE PRESIDENT, CLINICAL OPERATIONS

Dr Karen O'Hanlon joined Boyds in 2019 as the Vice President, Clinical Operations. Karen has more than 20 years' experience in preclinical, clinical and analytical drug development and has a strong track record of leading experienced project teams across all functions. Karen has expertise across multiple therapeutic areas including the clinical development of oncology, gene therapies and vaccine products. Previously, Karen owned Blue Duck Consultancy Ltd which she set up in 2013 to provide program and project management for preclinical and clinical phase I-IV studies through a global network of CRA consultants. Karen's role involved the oversight and management of a team of global CRAs to support clients with study start up activities, clinical study monitoring, feasibility studies, medical writing and training. Karen's career has spanned various project management roles including Project Director at hVIVO, Clinical and Laboratory Project Manager and Feasibility and Program Manager at SRA Global Clinical Development and Preclinical and Clinical Project Manager at MediGene GmbH. Prior to this, Karen was a Consultant Project Manager (veterinary medicine) at Triveritas and a Preclinical Business Co-Ordinator (Program Manager) and Project Leader (in vivo metabolism) at Charles River Laboratories. Karen completed her post-doctoral research at the Wellcome Trust Centre for Cell Matrix Research in Manchester. She has a BSc (Hons) in Medical Biochemistry from the University of Glasgow and a PhD in Biochemistry from the University of Manchester.

Job Titles:

• VICE PRESIDENT, BUSINESS DEVELOPMENT

Job Titles:

• VICE PRESIDENT, PRODUCT DEVELOPMENT

Job Titles:

• Boyds' VP and Head of US Regulatory Affairs
• VICE PRESIDENT and HEAD of US REGULATORY AFFAIRS
• Vice President, Head of US Regulatory Affairs

As Boyds' VP and Head of US Regulatory Affairs, Katy effectively utilizes her knowledge of the global pharmaceutical industry to support our US-based clients and facilitate our many interactions with the FDA.

Job Titles:

• CHIEF FINANCIAL OFFICER
• Financial Leader and Chief Financial Officer

Neil Chakrabarti is an experienced financial leader and Chief Financial Officer at Boyds. Neil Chakrabarti has worked with a number of businesses across the sector including biotech start-up Atolls Therapeutics plc, pharma business Vectura Group plc, leading multinational medical device manufacturer Medtronic plc, and private equity-backed business Independent Clinical Services. He has a track record in providing robust financial leadership and adding measurable value to the organisations he has worked with. Neil was appointed interim chief financial officer in March 2021 and is an integral part of the Boyds' management team. His role includes supporting the development of business strategy and overseeing the improvement of systems and processes to support growth and help improve efficiencies across the business. Neil is a Chartered Global Management Accountant (CIMA), has a Masters of Chemical Engineering from the University Leeds and completed an MBA at Cranfield School of Management.

Job Titles:

• CONSULTANT
• MARKETING DIRECTOR
• Member of the Executive Management Group

Sue Carr has worked with Boyds as their Consultant Marketing Director since 2013. Sue Carr has over 20 years of marketing experience. Her past experience includes Head of National Marketing at Tenon and Marketing Director at Berryman (now Shakespeare Martineau). As a member of the Executive Management Group at Boyds, Sue is responsible for setting the marketing strategy, supporting growth plans and overseeing the implementation of marketing and PR.

Job Titles:

• Director of Marketing and Communications

Sue is a director of marketing and communications consultancy V Formation and is based at BioCity in Nottingham.